Colossal Biosciences, a Dallas, TX-based de-extinction company, raised $200M in Series C Funding.
Backers included TWG Global. Other investors included USIT, Animal Capital, Breyer Capital, At One Ventures, In-Q-Tel, BOLD Capital, Peak 6, Draper Associates, Robert Nelsen, Peter Jackson, Fran Walsh, Ric Edelman, Brandon Fugal, Paul Tudor Jones, Richard Garriott, Giammaria Giuliani, Sven-Olof Lindblad, Victor Vescovo, and Jeff Wilke.
The company intends to use the funds to continue to advance its genetic engineering technologies while pioneering new software, wetware and hardware solutions, which have applications beyond de-extinction including species preservation and human healthcare.
Founded by Ben Lamm and George Church, Colossal creates technologies for species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth.
The company employs over 170 scientists and partners with labs in Boston, Dallas, and Melbourne, Australia. In addition, it sponsors over 40 full time postdoctoral scholars and research programs in 16 partner labs at some of the most prestigious universities around the globe. Its scientific advisory board has grown to include over 95 of the top scientists working in genomics, ancient DNA, ecology, conservation, developmental biology, and paleontology.
FinSMEs
15/01/2025